Keywords: Denosumab, Giant-cell tumor, Ph II, Amgen, Xgeva, Prolia, Santa Monica Oncology Center

Denosumab reduces burden of giant-cell tumor of the bone

Article | 25 September 2012

Print This

Treatment with denosumab, a drug from Amgen (Nasdaq: AMGN), the world’s largest biotech firm which markets the compound ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in